1-3 of 3
Michel Ducreux
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Timothy J. Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor E. Ciuleanu, Laslo Roman, Eric Van Cutsem, Pei He, Hua Yu, Reija Koukakis, Jan-Henrik Terwey, Andre S. Jung, Roger Sidhu, Scott D. Patterson
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5469–5479.
https://doi.org/10.1158/1078-0432.CCR-15-0526
Published: 14 December 2015
View article titled, Analysis of <em>KRAS</em>/<em>NRAS</em> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Open the PDF for Analysis of <em>KRAS</em>/<em>NRAS</em> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients

Justin Guinney, Charles Ferté, Jonathan Dry, Robert McEwen, Gilles Manceau, KJ Kao, Kai-Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean-Charles Soria, Stephen Friend, Jonathan Derry, Pierre Laurent-Puig
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 265–272.
https://doi.org/10.1158/1078-0432.CCR-13-1943
Published: 05 January 2014
View article titled, Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Open the PDF for Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients in another window
Includes: Supplementary data
Journal Articles

ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

Jérôme Viguier, Valérie Boige, Catherine Miquel, Marc Pocard, Bruno Giraudeau, Jean-Christophe Sabourin, Michel Ducreux, Alain Sarasin, Françoise Praz
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6212–6217.
https://doi.org/10.1158/1078-0432.CCR-04-2216
Published: 06 September 2005
View article titled, <em>ERCC1</em> Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer
Open the PDF for <em>ERCC1</em> Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer in another window